Loading clinical trials...
Loading clinical trials...
A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Non-Fasting Conditions
Conditions
Interventions
Cefdinir for oral suspension 250 mg/5mL
OMNICEF® for oral suspension 250 mg/5mL
Locations
2
United States
Novum Pharmaceutical Research Services
Houston, Texas, United States
Bioassay Laboratory, Inc.
Houston, Texas, United States
Start Date
March 1, 2005
Primary Completion Date
March 1, 2005
Completion Date
March 1, 2005
Last Updated
August 20, 2024
NCT06716502
NCT07310264
NCT06290258
NCT00090662
NCT07483606
NCT06342713
Lead Sponsor
Teva Pharmaceuticals USA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions